Roger B. Lee
University of Chicago
30 Papers
87 Citations
Roger B. Lee is an academic researcher from University of Chicago. The author has contributed to research in topics: Medicine & Carboplatin. The author has an hindex of 13, co-authored 25 publications. Previous affiliations of Roger B. Lee include Case Western Reserve University & University of Washington.
Chat about Author
Papers
A randomized phase III trial in advanced endometrial carcinoma of surgery and volume directed radiation followed by cisplatin and doxorubicin with or without paclitaxel: A Gynecologic Oncology Group study☆☆☆
Howard D. Homesley,Virginia L. Filiaci,Susan K. Gibbons,Harry J. Long,David Cella,Nick M. Spirtos,Robert T. Morris,Koen DeGeest,Roger B. Lee,Anthony G. Montag +9 more
TL;DR: The addition of paclitaxel to cisplatin and doxorubicin following surgery and radiation was not associated with a significant improvement in RFS but was associated with increased toxicity.
237
Phase II study of medroxyprogesterone acetate plus tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study.
Charles W. Whitney,Virginia L. Brunetto,Richard J. Zaino,Samuel S. Lentz,Joel I. Sorosky,Deborah K. Armstrong,Roger B. Lee +6 more
TL;DR: The combination of daily tamoxifen and intermittent weekly medroxyprogesterone acetate is an active treatment for advanced or recurrent endometrial carcinoma and further investigation of this combination is appropriate.
190
Phase II Evaluation of Imatinib Mesylate in the Treatment of Recurrent or Persistent Epithelial Ovarian or Primary Peritoneal Carcinoma: A Gynecologic Oncology Group Study
Russell J. Schilder,Michael W. Sill,Roger B. Lee,Tanya J. Shaw,Mary K. Senterman,Andres J. Klein-Szanto,Zoe Miner,Barbara C. Vanderhyden +7 more
TL;DR: Imatinib mesylate was well tolerated but had minimal single-agent activity in patients with recurrent ovarian or primary peritoneal carcinoma and no marker was identified that would predict activity of imatinib; however, tumor p-AKT and plasma VEGF levels were associated with poor outcome.
115
Adjuvant whole abdominal irradiation in clinical stages I and II papillary serous or clear cell carcinoma of the endometrium: A phase II study of the Gynecologic Oncology Group
Gregory P. Sutton,Janice H. Axelrod,Brian N. Bundy,Tapan Roy,Howard D. Homesley,Roger B. Lee,Paola A. Gehrig,Richard J. Zaino +7 more
TL;DR: Systemic chemotherapy, radiosensitizing chemotherapy, or sequential radiation and chemotherapy should be considered in future adjuvant trials for patients with clinical stage I/II papillary serous or clear cell endometrial carcinoma treated with whole abdominal radiotherapy.
95
Surgical complications of obese patients with endometrial carcinoma.
Katherine S. Foley,Roger B. Lee +1 more
TL;DR: Obese patients with exploratory laparotomy for stage I and II adenocarcinoma of the endometrium had significantly higher rates of wound infection and wound dehiscence, longer operating time, greater blood loss, and longer hospital stay.
79